Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the ASPECT-cUTI trial (Q39905753)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the ASPECT-cUTI trial	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

15 September 2017

Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the ASPECT-cUTI trial (English)

1 reference

Europe PubMed Central

15 September 2017

urinary tract infection

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

George Sakoulas

2

object named as

George Sakoulas

1 reference

Europe PubMed Central

15 September 2017

Ellie J. C. Goldstein

7

object named as

Ellie J C Goldstein

1 reference

Europe PubMed Central

15 September 2017

author name string

Jennifer A Huntington

1

1 reference

Europe PubMed Central

15 September 2017

Obiamiwe Umeh

3

1 reference

Europe PubMed Central

15 September 2017

Daniel J Cloutier

4

1 reference

Europe PubMed Central

15 September 2017

Judith N Steenbergen

5

1 reference

Europe PubMed Central

15 September 2017

Caleb Bliss

6

1 reference

Europe PubMed Central

15 September 2017

language of work or name

0 references

publication date

18 March 2016

1 reference

Europe PubMed Central

15 September 2017

Journal of Antimicrobial Chemotherapy

1 reference

Europe PubMed Central

15 September 2017

71

1 reference

Europe PubMed Central

15 September 2017

2014-2021

1 reference

Europe PubMed Central

15 September 2017

7

1 reference

Europe PubMed Central

15 September 2017

Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW053

21 January 2018

Health care-associated infections: a meta-analysis of costs and financial impact on the US health care system.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW053

21 January 2018

Epidemiology, treatment and prevention of healthcare-associated urinary tract infections

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW053

21 January 2018

Appropriate antibiotic use for patients with urinary tract infections reduces length of hospital stay

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW053

21 January 2018

Costs of healthcare- and community-associated infections with antimicrobial-resistant versus antimicrobial-susceptible organisms

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW053

21 January 2018

Impact of extended-spectrum β-lactamase-producing organisms on clinical and economic outcomes in patients with urinary tract infection.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW053

21 January 2018

Impact of discordant empirical therapy on outcome of community-acquired bacteremic acute pyelonephritis.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW053

21 January 2018

Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW053

21 January 2018

Healthcare-associated urinary tract infections in hospitalized urological patients--a global perspective: results from the GPIU studies 2003-2010.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW053

21 January 2018

Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012).

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW053

21 January 2018

Mechanism of plasmid-mediated quinolone resistance

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW053

21 January 2018

Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW053

21 January 2018

Fluoroquinolone resistance among gram-negative urinary tract pathogens: global smart program results, 2009-2010

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW053

21 January 2018

Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW053

21 January 2018

Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. Hospitals (2011-2012).

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW053

21 January 2018

Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI).

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW053

21 January 2018

Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW053

21 January 2018

Antimicrobial susceptibility of inpatient urinary tract isolates of gram-negative bacilli in the United States: results from the study for monitoring antimicrobial resistance trends (SMART) program: 2009-2011.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW053

21 January 2018

Declining susceptibilities of gram-negative bacteria to the fluoroquinolones: effects on pharmacokinetics, pharmacodynamics, and clinical outcomes

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW053

21 January 2018

Pharmacokinetic characteristics of antimicrobials and optimal treatment of urosepsis

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW053

21 January 2018

Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW053

21 January 2018

Emerging resistance problems and future perspectives in pharmacotherapy for complicated urinary tract infections

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW053

21 January 2018

Levofloxacin for the treatment of pyelonephritis

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW053

21 January 2018

Temporal trends and risk factors for extended-spectrum beta-lactamase-producing Escherichia coli in adults with catheter-associated urinary tract infections

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW053

21 January 2018

Identifiers

10.1093/JAC/DKW053

1 reference

Europe PubMed Central

15 September 2017

1 reference

Europe PubMed Central

15 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39905753&oldid=2068501558"